Scilex Holding Company × Datavault AI Inc.
Datavault AI granted Scilex an exclusive worldwide license for its AI-driven data tokenization platform for use in the biotech and biopharma industry. [36] In exchange, Scilex agreed to pay a $10 million non-refundable license fee in four installments starting December 31, 2025, plus potential sales-based milestones up to $2.55 billion and a 5% royalty on net sales. [49]
The asset
An exclusive worldwide license for Datavault AI's proprietary AI-driven technology, enabling Scilex to create and operate a Biotech Exchange platform for the tokenization and monetization of genomic, DNA, diagnostic, and drug data. [36, 46]
The record
- Seller status
- Going concern
- Sector
- AI and data monetization
- Modalities
- genomic_data, drug_data, diagnostics_data, platform_technology
- Jurisdiction
- US
- Personal data
- The platform is designed for the tokenization of data, which implies a form of de-identification or pseudonymization, but specific methods are not detailed in the announcements.
What it means if you hold data
This deal highlights the emerging market for tokenizing real-world assets (RWAs) in the life sciences, creating a new mechanism for monetizing and trading valuable health data like genomic and drug information. It represents a significant bet on blockchain-based platforms to provide liquidity and funding avenues in biotech.